Table 2.
Descriptive comparison between studies considered
| Source | Study design (add-on or monotherapy) |
Sample and sex (civilians or veterans) |
Range (and mean dose) (mg/d) | Duration | Effectiveness - changes from baseline assessment scores | AMSTAR 2 |
|---|---|---|---|---|---|---|
| Sattar et al. [15], 2002 | Case report (add-on to paroxetine) | 1 (100% male) (civilian) | 150 | 12 months | QTP associated with marked improvements in HAM-D and CAPS scores | NA |
| Filteau et al. [16], 2003 | Case series (add-on to SRI and GBP) | 5 (60% male) (civilians) | 150−200 | NA | NA | NA |
| Hamner et al. [17], 2003 | Open-label trial (add-on to psychotropic medication [SRI, anticonvulsants, sleep agents]) | 20 (95% male) (veterans) | 25−300 (100 ± 70) | 6 weeks | QTP associated with significant improvements in HAM-D, PANSS and CAPS scores | Moderate |
| Ahearn et al. [18], 2006 | Open-label trial (add-on to SSRI) | 15 (53% male) (civilians) | 100−400 (216) | 8 weeks | QTP associated with significant improvement in HAM-D, CGI-I/S, PSQI, CAPS scores | Moderate |
| Byers et al. [19], 2010 | Prospective cohort study (add-on to SSRI, sleep agents) | 270 (97% male) (veterans) | QTP 25−600 PRZ 1-25 |
≤ 6 months 3−6 years |
NA | Low |
| Detweiler et al. [20], 2016 | Retrospective study (monotherapy) | 327 (95% male) (veterans) | QTP 12.5−800 PRZ 1−20 RIS 0.25−6.0 |
4 years | NA | Low |
| Pivac and Kozarić-Kovacić [21], 2006 | Open-label trial (monotherapy) | 53 (100% male) (veterans) | 25−400 | 6 weeks | QTP associated with significant improvement in PANS, CGI-S, CAPS scores | Moderate |
| Sokolski et al. [22], 2003 | Retrospective study (add- on to SRI, anticonvulsants, antipsychotics) | 68 (100% male) (veterans) | 25−700 (155 ± 130) | 25 weeks | QTP associated with a marked improvement in CGI-I scores | Moderate |
| Villarreal et al. [23], 2016 | Randomized, double-blind, placebo-controlled trial (monotherapy) | 80 (100% male) (veterans) | 50−800 (258) | 12 weeks | QTP superior to PLC for CGI-S/I, PANSS, HAM-A, HAM-D, CAPS | Moderate |
| Baig et al. [24], 2019 | Retrospective study (add-on to SRI, mood stabilizers, sleep agents) | 50 (96% male) (veterans) | QTP 50−400 (180) VPA 500−2,000 (1,625) RIS 1−4 (2) |
10−12 weeks | NA | Low |
QTP, quetiapine; HAM-D, Hamilton Depression Rating Scale; PTSD, posttraumatic stress disorder; CAPS, Clinician Administered PTSD Scale; SRI, serotonin reuptake inhibitor; GBP, gabapentin; VPA, valproate; PLC, placebo; SSRI, selective serotonin reuptake inhibitors; PANSS, Positive and Negative Syndrome Scale; CGI-I/S, Clinical Global Impression-Improvement/Severity; PSQI, Pittsburgh Sleep Quality Index; PRZ, prazosin; RIS, risperidone; NA, not available.